New drug class shows promise for millions with heart failure

A clinical trial found that blocking an inflammatory enzyme called myeloperoxidase may help heart failure patients whose hearts still pump reasonably well. The finding could open a new treatment avenue for a large, underserved patient population and reshape how cardiologists approach this growing condition.

Originaltitel: Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results